

AMENDMENTS TO THE CLAIMS

1. (previously presented) A method of inducing systemic tolerance to an antigen in an individual in need of such treatment, comprising the step of:

administering to said individual antigen presenting cells which (1) express high levels of Fas ligand resulting from co-infection with AdLoxFasL and AxCANCre adenoviruses, (2) do not express Fas and (3) express said antigen, wherein said antigen presenting cells induce apoptosis of Fas-positive T cells directed towards said antigen resulting in said induction of systemic tolerance to said antigen.

2. (canceled)

3. (original) The method of claim 1, wherein said antigen is selected from the group consisting of the adenovirus antigen, a viral antigen, an adeno-associated viral antigen, an autoantigen, and an alloantigen.

4. (original) The method of claim 1, wherein said individual has an autoimmune disease.

5. (original) The method of claim 4, wherein said autoimmune disease is selected from the group consisting of diabetes, multiple sclerosis, rheumatoid arthritis, thyroiditis, Grave's disease, systemic lupus erythematosus.

6. (original) The method of claim 1, wherein said individual has had an organ transplant.

7. (canceled)

8. (previously presented) The method of claim 1, further comprising the step of delivering *in vitro* to said antigen presenting cells a gene to inhibit apoptosis.

9. (original) The method of claim 8, wherein said gene to inhibit apoptosis is *crmA*.

10-17. (canceled)